efineptakin alpha
Recombinant proteinexperimental
Clinical trial activity
8 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2020 (NCT04380948)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Squamous Cell · Phase 1
- Esophageal Neoplasms · Phase 2
- Glioblastoma · Phase 2
- Gliosarcoma · Phase 2
- HIV Infections · Phase 1
- Neoplasms · Phase 2
- Sarcoma, Kaposi · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
Mechanism of action
- PAC1-PAC2 complexSupplementation
PAC1-PAC2 complex supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594590 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07269158 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2025 | Yonsei University |
| NCT05465954 | Phase 2 | Jan 15, 2023 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT05145907 | Phase 2 | Dec 31, 2021 | I-Mab Biopharma |
| NCT04893018 | Phase 1 | Dec 1, 2021 | Cancer Immunotherapy Trials Network, University of California, San Francisco, University of Washington |
| NCT04984811 | Phase 2 | Nov 3, 2021 | NeoImmuneTech, Inc., Roche |
| NCT04588038 | Phase 1 | Mar 12, 2021 | NeoImmuneTech, Inc., University of California, San Francisco |
| NCT04594811 | Phase 2 | Jan 7, 2021 | Bristol-Myers Squibb, NeoImmuneTech, Inc. |
| NCT04380948 | Phase 1 | Jul 31, 2020 | Washington University in St. Louis |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NeoImmuneTech, Inc. | For profit | 3 | 2 | 2 | 2021 |
| University of California, San Francisco | Academic/Hospital | 2 | 1 | 1 | 2021 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2021 |
| Cancer Immunotherapy Trials Network | Academic/Hospital | 1 | 0 | 1 | 2021 |
| I-Mab Biopharma | For profit | 1 | 1 | 1 | 2021 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2023 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2023 |
| Roche | For profit | 1 | 0 | 1 | 2021 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2025 |
11 organizations
Page 1 / 1